CASI PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
CASI PHARMACEUTICALS, INC. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-29.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2019-03-29
- CASI PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-12-31 was $4.14M, a 102.33% increase year-over-year.
- CASI PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- CASI PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- CASI PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- CASI PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- CASI PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2017 was $4.14M, a 21.55% decline from fiscal 2016.
- CASI PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2016 was $5.28M.
- CASI PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2015 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-29 | |||
| 2017-12-31 | $4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $4.14M derived: sum of 2 quarters · filed 2019-03-29 | $4.14M derived: sum of 3 quarters · filed 2019-03-29 | $4.14M 10-K · filed 2019-03-29 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $0.00 derived: sum of 2 quarters · filed 2017-11-14 | $0.00 10-Q · filed 2017-11-14 | $2.05M derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | $2.05M derived: sum of 3 quarters · filed 2018-03-29 | $2.24M derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | $2.05M derived: sum of 2 quarters · filed 2018-03-29 | $2.24M derived: sum of 3 quarters · filed 2018-03-29 | $3.36M derived: sum of 4 quarters · filed 2018-03-29 |
| 2016-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $2.24M derived: sum of 2 quarters · filed 2018-03-29 | $3.36M derived: sum of 3 quarters · filed 2018-03-29 | $5.28M 10-K · filed 2018-03-29 |
| 2016-09-30 | $188.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $1.31M derived: sum of 2 quarters · filed 2017-11-14 | $3.23M 10-Q · filed 2017-11-14 | $3.23M derived: sum of 4 quarters · filed 2017-11-14 |
| 2016-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $3.04M 10-Q · filed 2017-08-14 | $3.04M derived: sum of 3 quarters · filed 2017-08-14 | $3.04M derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | $1.92M 10-Q · filed 2017-05-15 | $1.92M derived: sum of 2 quarters · filed 2017-05-15 | $1.92M derived: sum of 3 quarters · filed 2017-05-15 | $1.92M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $0.00 derived: sum of 2 quarters · filed 2017-03-31 | $0.00 derived: sum of 3 quarters · filed 2017-03-31 | $0.00 10-K · filed 2017-03-31 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $0.00 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-13 |